A Phase III, Double Blind, Mulit-Centre, Randomised Placebo Controlled, Pilot Study to Assess the Feasibility of Switching Individuals Receiving Efavirez With Continuing Central Nervous System (CNS) Toxicity to TMC125.
Phase of Trial: Phase III
Latest Information Update: 06 Nov 2012
At a glance
- Drugs Etravirine (Primary) ; Efavirenz; Nucleoside reverse transcriptase inhibitors
- Indications HIV-1 infections
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 20 Nov 2009 Actual patient number (24) added as reported by ClinicalTrials.gov.
- 20 Nov 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.